WO1992013570A3 - Nouveaux complexes contenant de l'acide nucleique absorbables par endocytose par des cellules eucaryotes superieures - Google Patents

Nouveaux complexes contenant de l'acide nucleique absorbables par endocytose par des cellules eucaryotes superieures Download PDF

Info

Publication number
WO1992013570A3
WO1992013570A3 PCT/EP1992/000217 EP9200217W WO9213570A3 WO 1992013570 A3 WO1992013570 A3 WO 1992013570A3 EP 9200217 W EP9200217 W EP 9200217W WO 9213570 A3 WO9213570 A3 WO 9213570A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
eucaryotic cells
absorbed
higher eucaryotic
complexes
Prior art date
Application number
PCT/EP1992/000217
Other languages
German (de)
English (en)
Other versions
WO1992013570A2 (fr
Inventor
Max L Birnstiel
Matthew Cotten
Ernst Wagner
Original Assignee
Boehringer Ingelheim Int
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Genentech Inc filed Critical Boehringer Ingelheim Int
Priority to DE59207189T priority Critical patent/DE59207189D1/de
Priority to EP92903641A priority patent/EP0571414B1/fr
Priority to JP4503508A priority patent/JPH06504993A/ja
Priority to US08/098,265 priority patent/US5922859A/en
Publication of WO1992013570A2 publication Critical patent/WO1992013570A2/fr
Publication of WO1992013570A3 publication Critical patent/WO1992013570A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Des complexes de conjugués de facteur de liaison et de facteur d'intériorisation d'une part, et d'acide nucléique d'autre part, susceptibles d'être assimilés par endocytose par des cellules eucaryotes supérieures, contiennent sous une forme liée par non-covalence une ou plusieurs substances ayant une affinité avec l'acide nucléique et capables d'augmenter l'absorbabilité des complexes par des cellules. Le cas échéant, la substance liée par non-covalence ayant une affinité avec l'acide nucléique est identique au facteur de liaison, de préférence une substance polycationique. Le facteur d'intériorisation est de préference la transferrine. L'invention concerne également un procédé de production de ces complexes et un procédé d'introduction d'acide nucléique dans des cellules eucaryotes supérieures, ainsi que des compositions pharmaceutiques contenant des complexes avec un acide nucléique à effet thérapeutique.
PCT/EP1992/000217 1991-02-12 1992-02-01 Nouveaux complexes contenant de l'acide nucleique absorbables par endocytose par des cellules eucaryotes superieures WO1992013570A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE59207189T DE59207189D1 (de) 1991-02-12 1992-02-01 Neue, über endozytose in höhere eukaryotische zellen aufnehmbare, nukleinsäure enthaltende komplexe
EP92903641A EP0571414B1 (fr) 1991-02-12 1992-02-01 Nouveaux complexes contenant de l'acide nucleique absorbables par endocytose par des cellules eucaryotes superieures
JP4503508A JPH06504993A (ja) 1991-02-12 1992-02-01 エンドサイトーシスにより高等真核細胞に吸収されうる新規核酸含有複合体
US08/098,265 US5922859A (en) 1992-02-01 1992-02-01 Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4104186A DE4104186A1 (de) 1991-02-12 1991-02-12 Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
DEP4104186.0 1991-02-12

Publications (2)

Publication Number Publication Date
WO1992013570A2 WO1992013570A2 (fr) 1992-08-20
WO1992013570A3 true WO1992013570A3 (fr) 1992-10-29

Family

ID=6424859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1992/000217 WO1992013570A2 (fr) 1991-02-12 1992-02-01 Nouveaux complexes contenant de l'acide nucleique absorbables par endocytose par des cellules eucaryotes superieures

Country Status (6)

Country Link
EP (1) EP0571414B1 (fr)
JP (1) JPH06504993A (fr)
AT (1) ATE142890T1 (fr)
DE (2) DE4104186A1 (fr)
ES (1) ES2094342T3 (fr)
WO (1) WO1992013570A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945884B2 (en) 2000-12-11 2015-02-03 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US9534252B2 (en) 2003-12-01 2017-01-03 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
JPH0889278A (ja) * 1994-09-29 1996-04-09 Ajinomoto Co Inc 遺伝子導入用修飾蛋白質及びその製法
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JP4338106B2 (ja) * 1995-06-07 2009-10-07 ライフ テクノロジーズ コーポレーション ペプチド増強カチオン脂質トランスフェクション
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
FR2755976B1 (fr) 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
US6902933B2 (en) * 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
WO2004096117A2 (fr) * 2003-05-02 2004-11-11 Xpression Antibody Therapeutics, Inc. Systemes d'administration d'acides nucleiques
US20090093551A1 (en) * 2006-12-08 2009-04-09 Bhatia Sangeeta N Remotely triggered release from heatable surfaces
KR20150083920A (ko) 2012-11-15 2015-07-20 로슈 이노베이션 센터 코펜하겐 에이/에스 항 apob 안티센스 접합체 화합물
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
WO2016011203A1 (fr) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387775A1 (fr) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Unité génétique pour inhiber la fonction d'ARN
EP0388758A1 (fr) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Conjugé protéine-polycation
WO1991017773A2 (fr) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh Nouveaux conjugues de proteines et de polycations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387775A1 (fr) * 1989-03-16 1990-09-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Unité génétique pour inhiber la fonction d'ARN
EP0388758A1 (fr) * 1989-03-16 1990-09-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Conjugé protéine-polycation
WO1991017773A2 (fr) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh Nouveaux conjugues de proteines et de polycations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem., Band 2, Nr. 4, Juli/August 1991, American Chemical Society, (Washington, DC, US), E. WAGNER et al.: "DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety", Seiten 226-231, siehe das ganze Dokument (in der Anmeldung erwähnt) *
Proc. Natl. Acad. Sci. USA, Band 87, Mai 1990, (Washington, DC, US), E. WAGNER et al.: "Transferrin-polycation conjugates as carriers for DNA uptake into cells", Seiten 3410-3414, siehe das ganze Dokument *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents
US9309520B2 (en) 2000-08-21 2016-04-12 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US8945884B2 (en) 2000-12-11 2015-02-03 Life Technologies Corporation Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites
US9534252B2 (en) 2003-12-01 2017-01-03 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same

Also Published As

Publication number Publication date
JPH06504993A (ja) 1994-06-09
DE4104186A1 (de) 1992-08-13
WO1992013570A2 (fr) 1992-08-20
EP0571414B1 (fr) 1996-09-18
DE59207189D1 (de) 1996-10-24
ATE142890T1 (de) 1996-10-15
EP0571414A1 (fr) 1993-12-01
ES2094342T3 (es) 1997-01-16

Similar Documents

Publication Publication Date Title
WO1992013570A3 (fr) Nouveaux complexes contenant de l'acide nucleique absorbables par endocytose par des cellules eucaryotes superieures
EP0294703A3 (en) Bifunctional antibody constructs and method for selectively destroying cell populations
AU3196795A (en) Linked peptide nucleic acids
AU1375188A (en) Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
WO1991017773A3 (fr) Nouveaux conjugues de proteines et de polycations
AU1987888A (en) Improvements in and relating to packaging
ES2112982T3 (es) Composicion relativa a una bebida dietetica.
EP0185374A3 (en) Liquid diclofenac preparations
IL101225A0 (en) Bi-and tricyclic amino alcohol esters,their preparation and pharmaceutical compositions containing them
CA2298659A1 (fr) Antalgique d'action rapide
AU5957986A (en) Vector for the expression of gamma-interferon in mammal cells, method for its implementation, product obtained and pharmaceutical composition containing the gamma-interferon
IL105503A0 (en) Active compounds
CA2351620A1 (fr) Emulsion nanometrique d'acide 5-aminolevulinique
DK154537C (da) Hurtig-disintegrerende komprimerede laegemiddelpraeparater
GR3036634T3 (en) Novel protein polycation conjugates.
AU586237B2 (en) Non dusty blends of meals or flours with active principles for use in fodder production
EP0217992A3 (fr) Lyse ou blocage de cellules non-désirées
AU3073789A (en) Drug delivery using pulmonary surfactant to facilitate absorption
CA2227241A1 (fr) Procede pour diminuer la dose de rayons ou de chimiotherapie radio-mimetique en vue d'une greffe de cellules hematopoietiques pluripotentes
AU586988B2 (en) Solid drug formulations and stable suspensions
EP0745672A3 (fr) Production du facteur VIII recombinant en présence de mélanges de composés du type liposomes
WO1992019281A3 (fr) Nouveaux conjugues composes d'une glycoproteine et d'une substance liant des acides nucleiques
CA2254772A1 (fr) Traitements liposomaux par antineoplastons presentant une activite antineoplasique nettement amelioree
AU522139B2 (en) Immunogenic cell envelope preparations
Krasnikov et al. Crystal structure of the double triphosphate FeNH sub (4) HP sub (3) O sub (10).

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992903641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08098265

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1992903641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992903641

Country of ref document: EP